Vigabatrin API

Name	Vigabatrin
Chinese name	氨己烯酸
Cas Number	60643-86-9
Source	India
Qualifications	USDMF/-/-/-/-

Vivaroxenic acid was developed by Lundbeck Pharmaceuticals and was approved for marketing by the US FDA in August 2009. It is the only drug approved by the FDA for the treatment of infantile spasms. Gamma-aminobutyric acid can form an irreversible combination with neuronal γ-aminobutyric acid transaminase by covalent bonds, blocking the decomposition pathway of GABA, thereby increasing the content of γ-aminobutyric acid in the brain, and then exhibiting anti-epileptic properties effect. Compared with gabapentin, vigabatrin has a higher bioavailability and a longer half-life, and the effective time of vigabatrin is significantly longer than the half-life. Vivaroxenic acid can treat epilepsy for which other antiepileptic drugs are ineffective, especially patients with partial seizures (mainly used to control complex partial seizures), but it has an irreplaceable role in the treatment of intractable epilepsy. Currently abroad, vigabatrin has replaced ACTH as the first-line treatment for infantile spasms. In 2018, the global sales of vigabatrin were RMB 1.392 billion.

Hot Tags: vigabatrin api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Vinpocetine API, Canagliflozin API, Tippyridine Hydrochloride API, Dimethyl Fumarate API, Letrozole API, Temozolomide API

• Previous: Amiodarone Hydrochloride API
• Next: Lauroyl Aripiprazole API